
Escalating Drug Prices: Not All Is What It Seems

EMAIL (MAILTO:? FACEBOOK LINKEDIN TWITTER REDDIT
SUBJECT=ESCALATING+DRUG (HRITDESYMANAMEGGBBOOK-40-0455HPASSAMABABGBEPHINTO-MASGRIBBASSAMETO-STANDAME CALATING-PRICES-NOTDRUG-PRICES-NOTALL-WHAT-IT-SEEMSDRUG-PRICES-NOTDRU

4, 2016



Pharmaceutical companies, never America's darlings even on a good day, have been hammered mercilessly over the past few months, starting with the vile Martin Shkreli, followed by the scoundrels at Valeant, who objected rather vehemently when I referred to them as being one step below head lice on the food chain of life

PBMs in the living room with a calculator

(http://acsh.org/news/2016/03/02/female-viagra-rip-no-libido-and-no-libidough/).

Then it was generic giant Mylan's turn in the bulls-eye for their infamous \$600 EpiPen (http://acsh.org/news/2016/08/25/why-epipen-and-other-off-patent-drugs-are-so-expensive). But, should all of the blame fall on Mylan, or is there something else going on?

It turns out that there is quite a bit going on, it's just behind the scenes. And it isn't the FDA backlog or bureaucracy.


According to Earl L. "Buddy" Carter (R-Ga.), the only pharmacist in Congress, we ought to be looking more closely at the middlemen— Pharmacy Benefit Managers (PBMs) - who are the intermediaries between whatever company or agency that pays for drugs and the buyers of the drugs. They provide services like running mail-order pharmacies and negotiating prices with both retailers and drug makers.

Rep. Carter is troubled by the impact of high drug prices, which is evident from the following quote from his recent piece (http://thehill.com/blogs/congress-blog/healthcare/298582-the-man-behind-the-curtain-in-drug-price-increases) in The Hill:

"As a pharmacist for more than 30 years, and the only pharmacist in Congress, I've seen firsthand the anguish of families balancing their health care needs with their bottom line. It is indescribably heart wrenching to see a mother decide whether to buy groceries or her child's medication, or a senior citizen struggle to pay for medicine on a fixed budget."

And it also obvious where he places the blame:

Video



More videos » (/video)

Drug shortages worsen The blame game continues (/news/2014/02/11/drugshortages-worsen-blame-gamecontinues)

Related articles

Why The EpiPen And Other Generic Drugs Are So Expensive (/news/2016/08/25/why-epipenand-other-off-patent-drugs-areso-expensive)

Fact Checking Mylan Claims They Raised The EpiPen Price Because of Improvements (/news/2016/08/25/factchecking-mylan-claims-theyraised-the-epipen-pricebecause-of-improvements)

Internet Drugs? Be Careful (/news/2008/06/11/internet-drugs-be-careful)

Before The EpiPen And Daraprim There Was Naloxone — Generic Price Gouging Has A History (/news/2016/09/02/epipen-anddaraprim-there-was-naloxone-%E2%80%94-generic-pricegouging-has-history-9940)

Popular Content

A Vaccine For Herpes Erupts in the News (/news/2016/03/10/vaccine-herpes-erupts-news-9932)

When is the Best Time to Get A Flu Shot? (/news/2016/10/03/whenbest-time-get-flu-shot-10242)

Hybrid Antibiotic Created with Molecular 'Rope' Kills Resistant Bacteria (/news/2016/10/04/hybridantibiotic-created-molecularrope-kills-resistant-bacteria-10251)

ACSH Explains: Autophagy Wins 2016 Nobel Prize for Medicine. What Is It? (/news/2016/10/03/acsh-explains-autophagy-wins-2016-nobel-prize-medicine-what-it-10247)

Escalating Drug Prices: Not All Is What It Seems (/news/2016/10/04/escalating-drug-prices-not-all-what-it-seems-10236)



Inanimate Objects in Orifices (/news/2016/09/02/inanimate-objects-orifices-9964)

Pediatricians To Crack Down

Since their creation, however, PBMs have evolved from fiscal intermediaries into companies that dictate the products and providers used by patients to treat their medical conditions. This evolution has resulted in fewer choices in care for patients and the erosion of free market principles that truly drive prices down.

As far back as 2011, PBMs were already on the radar. Thomas Gryta, writing in the Wall Street Journal made this clear (http://www.wsj.com/articles/SB10001424053111903554904576460322664055328); (emphasis mine) "Pharmaceutical benefit managers process prescriptions for the groups that pay for drugs, usually insurance companies or corporations, and use their size to negotiate with drug makers and pharmacies. This latest deal [Express Scipts' pending \$29 billion purchase (http://phx.corporate-ir.net/phoenix.zhtml?c=69641&p=irolnewsArticle&ID=1679001) of Medco Health Solutions] the continues the consolidation trend but also **highlights** how the industry is becoming more than just an administrator and negotiator."

So that settles it, right? No, Phil Zweig, the Executive Director of Physicians Against Drug Shortages (http://www.physiciansagainstdrugshortages.com/), steadfastly maintains that most of the blame for inflated drug prices can be laid on Group Purchasing Organizations (GPOs)—middlemen between suppliers and (mostly) institutions, especially hospitals. Zweig, a former reporter for the Wall Street Journal and editor at Business Week, is critical of GPOs, which he simply calls "market makers." Zweig says that "GPOs contract for an estimated \$300 billion annually in drugs, devices and supplies and do little except write exclusive contracts for the highest bidder."

"The real middlemen that are driving the price of generic drugs are GPOs, which write exclusive contracts to the highest bidder. They are reminiscent to the Central Planning Committee from the old Soviet Union."

Physicians Against Drug Shortages also maintains that GPOs are responsible for the persistent drug shortages that have been plaguing patients and providers for a decade, though that is vehemently denied (http://www.drugshortage.org/p/what-others-are-saying.html) by the Healthcare Supply Chain Association.

Figuring out the causes of this critical issue is, of course, anything but simple, but what is clear is that a lot of blame is thrown around, and a huge sum of money is at the root of it all.

Coming up: HSCA responds.




Be the first to comment.

ALSO ON AMERICAN COUNCIL ON SCIENCE AND HEALTH

Kratom Is A Drug By Any Measure - Treat It Like One

125 comments • 6 days ago•



Patrick — 660 calls to poison control when the AKA estimates there could be as many as 3 - 5 million people using kratom in the U.S., and that number is based off ...

FDA warns against homeopathic teething remedies

26 comments • 5 days ago •



Josh Bloom — You are half right-- about the attitude. Perhaps you should learn how to read before you make comments: "Any parent who gives a kid who has ...

When is the Right Time to Get A Flu Shot?

4 comments • 3 days ago •



Hank Campbell — Yes, let's let such wisdom send us back to the days when life expectancy was 35 years.

Ben & Jerry's Asks Us to Take Big Lick of Fear & Hype

15 comments • 9 days ago •




hammurabix — If climate change is that much of an issue, perhaps we shouldn't be wasting money and generating the carbon footprint to produce a complete luxury good ... On Anti-Vaxx Parents, Policy Report Says (/news/2016/08/29/pediatricians crack-down-anti-vaxxparents-policy-report-says-9930)



Another Kardashian Craze Debunked (/news/2016/08/26/anotherkardashian-craze-debunked)

Celebs & Science: Sometimes It Works (/news/2016/04/04/celebsscience-sometimes-it-works)

Scientists Weigh in on Faulty Celebrity Health Claims (/news/2008/01/14/scientistsweigh-in-on-faulty-celebrityhealth-claims)



Will You Be Our Echo Chamber? (/news/2016/09/22/will-yoube-our-echo-chamber-10197)

NRDC Scientists Are Lying in the Weeds (/news/2016/04/20/nrdcscientists-are-lying-in-theweeds)

Now Dr. Oz is Against Fluoride Too? (/news/2016/02/02/80114)

Money, Fats, and Science (/news/2007/11/05/moneyfats-and-science)

Subscribe Add Disgus to your site Add Disgus Add Privacy

By Josh Bloom (/profile/josh-bloom)

(/profile/josh-bloom)

Senior Director of Chemical and Pharmaceutical Sciences



Dr. Josh Bloom earned a Ph.D. in organic chemistry from the University of Virginia, followed by postdoctoral training at the University of Pennsylvania. He worked for more than two decades in new drug discovery research at Lederle Laboratories, which was acquired by Wyeth in 1994, which itself was acquired by Pfizer in 2009.

During this time he conducted research in a number of therapeutic areas, including diabetes and obesity, antibiotics, HIV/AIDS, hepatitis C, and oncology. His group discovered

the novel antibiotic Tygacil®, which was approved by the FDA for use against resistant bacterial infections in 2005.

He is the author of 25 patents, and 35 academic papers, including a chapter on new therapies for hepatitis C in Burger's Medicinal Chemistry, Drug Discovery and Development, 7th Edition (Wiley, 2010), and has given numerous invited lectures on how the pharmaceutical industry really works.

Dr. Bloom joined the American Council on Science and Health in 2010 as ACSH's Director of Chemical and Pharmaceutical Sciences, and has written op-eds for numerous periocals, including for The Wall Street Journal, Forbes, New Scientist, The New York Post, National Review Online, The Boston Herals, and The Chicago Tribune. In 2014, Dr. Bloom was invited to become a featured writer for the site Science 2.0 (http://www.science20.com/), where he wrote more than 75 pieces on topics ranging from to the pharmaceutical industry, medicine, quackery, junk science, to anything that pissed him off at a given moment. Which can be pretty much anything.

Latest from Josh Bloom (/profile/josh-bloom):

Holding our Breath for New Antibiotics (/news/2016/10/05/holding-our-breath-new-antibiotics-10259)

Yes, Kratom Is a Drug: Here's Why (/news/2016/10/05/yes-kratom-drug-heres-why-10255)

Escalating Drug Prices: Not All Is What It Seems (/news/2016/10/04/escalating-drug-prices-not-all-what-it-seems-10236)

Herpes Vaccine Update: Exciting News, But Don't Throw Away Condoms Just Yet (/news/2016/09/26/herpes-vaccine-update-exciting-news-dont-throw-away-condoms-just-yet-10219)

Scrotox: An Idea That is Just Nuts (/news/2016/09/22/scrotox-idea-just-nuts-10203)

More » (/profile/josh-bloom)

Privacy Policy (/privacy-policy) Contact Us (/contact)

COPYRIGHT © 1978-2016 BY THE AMERICAN COUNCIL ON SCIENCE AND HEALTH

110 East 42nd Street, Suite 1300, New York, NY 10017

Telephone: 212-362-7044 | Email: info@acsh.org (mailto:info@acsh.org)